Brain neuronal nicotinic receptors as new targets for drug discovery

Current Pharmaceutical Design

Volumn 12, Issue 4, 2006, Pages 407-428

  Gotti, C ^a   Riganti, L ^a   Vailati, S ^a   Clementi, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Knock in mice; Knock out mice; Molecular structure; nAChRs in pathology; Neuronal nicotinic receptors; Nicotinic drugs; Toxins; Upregulation

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; A 366883; ABT 202; ACETYLCHOLINE; ALKALOID DERIVATIVE; ANABASINE; ANATOXIN A; BRAIN RECEPTOR; CHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTISINE; CYTISINE DERIVATIVE; EPIBATIDINE; ION CHANNEL; ISPRONICLINE; MORPHINE; NICOTINE; NICOTINE DERIVATIVE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; TC 2559; UB 165; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BINDING SITE; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEX FORMATION; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; IN VIVO STUDY; MENTAL DISEASE; MOLECULAR DYNAMICS; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; CYTOLOGY; DRUG DESIGN; DRUG EFFECT; METHODOLOGY; NERVE CELL; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; BRAIN; CHOLINERGIC AGENTS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; NEURONS; RECEPTORS, NICOTINIC; TECHNOLOGY, PHARMACEUTICAL;

EID: 33644885283     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474486     Document Type: Review

References (261)

1. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995; 57: 521-46.
2. Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996; 16(6): 1077-85.
3. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 1997; 53(2): 199-237.
4. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 1997; 15(2): 193-222.
5. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22(12): 555-61.
6. Changeux J, Edelstein SJ. Allosteric mechanisms in normal and pathological nicotinic acetylcholine receptors. Curr Opin Neurobiol 2001: 11(3): 369-77.
7. Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 2003; 147: 1-46.
8. Lindstrom J. The Structures of Neuronal Nicotinic Receptors. In: Clementi F, Fornasari D, Gotti C, editors. Handbook of Experimental Pharmacology. Berlin: Springer; 2000. p. 101-162.
9. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000; 61()1: 75-111.
10. Zanardi A, Leo G, Biagini G, Zoli M. Nicotine and neurodegeneration in ageing. Toxicol Lett 2002; 127(1-3): 207-15.
11. Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 1995; 40(2): 155-72.
12. Changeux JP, Edelstein SJ. Allosteric receptors after 30 years. Neuron 1998; 21(5): 959-80.
13. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002; 3(2): 102-14.
14. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 1993; 16: 403-43.
15. Sharma G, Vijayaraghavan S. Nicotinic receptor signaling in non-excitable cells. J Neurobiol 2002; 53(4): 524-34.
16. Palma E, Bertrand S, Binzoni T, Bertrand D. Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine. J Physiol 1996; 491 (Pt 1): 151-61.
17. Anand R, Conroy WG, Schoepfer R, Whiting P, Lindstrom J. Neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biol Chem 1991; 266(17): 11192-8.
18. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature 1991; 350(6315): 235-8.
19. Boorman JP, Groot-Kormelink PJ, Sivilotti LG. Stoichiometry of human recombinant neuronal nicotinic receptors containing the b3 subunit expressed in Xenopus oocytes. J Physiol 2000; 529 Pt 3: 565-77.
20. Corringer PJ, Le Novere N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000; 40: 431-58.
21. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, et al. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J Biol Chem 1996; 271(30): 17656-65.
22. Groot-Kormelink PJ, Luyten WH, Colquhoun D, Sivilotti LG. A reporter mutation approach shows incorporation of the "orphan" subunit beta3 into a functional nicotinic receptor. J Biol Chem 1998; 273(25): 15317-20.
23. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001; 411(6835): 269-76.
24. Smit AB, Syed NI, Schaap D, van Minnen J, Klumperman J, Kits KS, et al. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 2001; 411(6835): 261-8.
25. Sixma TK, Smit AB. Acetylcholine binding protein (AChBP): a secreted glial protein that provides a high-resolution model for the extracellular domain of pentameric ligand-gated ion channels. Annu Rev Biophys Biomol Struct 2003; 32: 311-34.
26. Dwoskin LP, Crooks PA. Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery. J Pharmacol Exp Ther 2001; 298(2): 395-402.
27. Americ SP, Holladay MW. Agonists and Antagonists of Nicotinic Acetylcholine Receptors. In: Clementi F, Fornasari D, Gotti C, editors. Handbook of Experimental Pharmacology. Berlin: Springer; 2000; p. 419-454.
28. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 2001; 92(2-3): 89-108.
29. Picciotto MR. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol Sci 2003; 24(9): 493-9.
30. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem 2004; 4(3): 369-84.
31. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 2004; 25(6): 317-24.
32. Zoli M, Lena C, Picciotto MR, Changeux JP. Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 1998; 18(12): 4461-72.
33. Perry DC, Xiao Y, Nguyen HN, Musachio JL, Davila-Garcia MI, Kellar KJ. Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem 2002; 82(3): 468-81.
34. Lena C, de Kerchove D'Exaerde A, Cordero-Erausquin M, Le Novere N, del Mar Arroyo-Jimenez M, Changeux JP. Diversity and distribution of nicotinic acetylcholine receptors in the locus ceruleus neurons. Proc Natl Acad Sci USA 1999; 96(21): 12126-31.
35. Ferreira M, Ebert SN, Perry DC, Yasuda RP, Baker CM, Davila-Garcia MI, et al. Evidence of a functional alpha7-neuronal nicotinic receptor subtype located on motoneurons of the dorsal motor nucleus of the vagus. J Pharmacol Exp Ther 2001; 296(2): 260-9.
36. Zoli M, Le Novere N, Hill JA, Jr., Changeux JP. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 1995; 15(3 Pt 1): 1912-39.
37. Cimino M, Marini P, Fornasari D, Cattabeni F, Clementi F. Distribution of nicotinic receptors in cynomolgus monkey brain and ganglia: localization of alpha 3 subunit mRNA, alpha-bungarotoxin and nicotine binding sites. Neuroscience 1992; 51(1): 77-86.
38. Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, et al. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 2002; 22(4): 1208-17.
39. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 2002; 22(20): 8785-9.
40. Tribollet E, Bertrand D, Marguerat A, Raggenbass M. Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience 2004; 124(2): 405-20.
41. Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994; 79(4): 705-15.
42. Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J. alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc Natl Acad Sci USA 2001; 98(6): 3501-6.
43. Han ZY, Le Novere N, Zoli M, Hill JA, Jr., Champtiaux N, Changeux JP. Localization of nAChR subunit mRNAs in the brain of Macaca mulatta. Eur J Neurosci 2000; 12(10): 3664-74.
44. Han ZY, Zoli M, Cardona A, Bourgeois JP, Changeux JP, Le Novere N. Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]alpha-bungarotoxin binding sites in the brain of Macaca mulatta. J Comp Neurol 2003; 461(1): 49-60.
45. Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, et al. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol 1989; 284(2): 314-35.
46. Wonnacott S, Wilkie GI, Soliakov L, Whitaker P. Presynaptic nicotinic autoreceptors and heteroreceptors in the CNS. In: Clarke PB, Quik M, Adlkofer F, Thurau K, editors. advances in Pharmacological Sciences. Effects of Nicotine on Biological Systems 11. Basel: Birkhauser Verlag; 1995. p. 87-94.
47. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997; 20(2): 92-8.
48. Wilkie GI, Hutson PH, Stephens MW, Whiting P, Wonnacott S. Hippocampal nicotinic autoreceptors modulate acetylcholine release. Biochem Soc Trans 1993; 21(2): 429-31.
49. Clarke PB, Reuben M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. Br J Pharmacol 1996; 117(4): 595-606.
50. Wonnacott S, Drasdo A, Sanderson E, Rowell P. Presynaptic nicotinic receptors and the modulation of transmitter release. In: Marsh J, editor. Ciba Foundation Symposium 152: The Biology of Nicotine Dependence. Chichester: Jhon Wiley and Sons; 1990. p. 87-101.
51. Rapier C, Lunt GG, Wonnacott S. Nicotinic modulation of [3H]dopamine release from striatal synaptosomes: pharmacological characterisation. J Neurochem 1990, 54(3): 937-45.
52. Grady S, Marks MJ, Wonnacott S, Collins AC. Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 1992; 59(3): 848-56.
53. Alkondon M, Pereira EF, Barbosa CT, Albuquerque EX. Neuronal nicotinic acetylcholine receptor activation modulates gamma-aminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther 1997; 283(3): 1396-411.
54. Yang X, Criswell HE, Breese GR. Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-containing neurons. J Pharmacol Exp Ther 1996; 276(2): 482-9.
55. McGehee DS. Nicotinic receptors and hippocampal synaptic plasticity ... it's all in the timing. Trends Neurosci 2002; 25(4): 171-2.
56. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001; 31(1): 131-41.
57. Picciotto MR, Caldarone BJ, King SL, Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 2000; 22(5): 451-65.
58. Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 2002; 22(9): 3338-41.
59. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP. Nicotinic receptor function: new perspectives from knockout mice. Trends Pharmacol Sci 2000; 21(6): 211-7.
60. Marubio LM, Changeux J. Nicotinic acetylcholine receptor knockout mice as animal models for studying receptor function. Eur J Pharmacol 2000; 393(1-3): 113-21.
61. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, et al. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 2003; 23(21): 7820-9.
62. Wang N, Orr-Urtreger A, Korczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol 2002; 68(5): 341-60.
63. Lester HA, Fonck C, Tapper AR, McKinney S, Damaj MI, Balogh S, et al. Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action. Curr Opin Drug Discov Devel 2003; 6(5): 633-9.
64. Drago J, McColl CD, Horne MK, Finkelstein DI, Ross SA. Neuronal nicotinic receptors: insights gained from gene knockout and knockin mutant mice. Cell Mol Life Sci 2003; 60(7): 1267-80.
65. Couturier S, Bertrand D, Matter JM, Hernandez MC, Bertrand S, Millar N, et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 1990; 5(6): 847-56.
66. Gerzanich V, Anand R, Lindstrom J. Homomers of alpha 8 and alpha 7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol Pharmacol 1994; 45(2): 212-20.
67. Sgard F, Charpantier E, Bertrand S, Walker N, Caput D, Graham D, et al. A novel human nicotinic receptor subunit, alpha10, that confers functionality to the alpha9-subunit. Mol Pharmacol 2002; 61(1): 150-9.
68. Alkondon M, Rocha ES, Maelicke A, Albuquerque EX. Diversity of nicotinic acetylcholine receptors in rat brain. V. alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release. J Pharmacol Exp Ther 1996; 278(3): 1460-71.
69. MacDermott AB, Role LW, Siegelbaum SA. Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 1999; 22: 443-85.
70. Berg DK, Conroy WG. Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 2002; 53(4): 512-23.
71. Shoop RD, Martone ME, Yamada N, Ellisman MH, Berg DK. Neuronal acetylcholine receptors with alpha7 subunits are concentrated on somatic spines for synaptic signaling in embryonic chick ciliary ganglia. J Neurosci 1999; 19(2): 692-704.
72. Palma E, Maggi L, Barabino B, Eusebi F, Ballivet M. Nicotinic acetylcholine receptors assembled from the alpha7 and beta3 subunits. J Biol Chem 1999; 274(26): 18335-40.
73. Khiroug SS, Harkness PC, Lamb PW, Sudweeks SN, Khiroug L, Millar NS, et al. Rat nicotinic ACh receptor alpha7 and beta2 subunits co-assemble to form functional heteromeric nicotinic receptor channels. J Physiol 2002; 540(Pt 2): 425-34.
74. Messi ML, Renganathan M, Grigorenko E, Delbono O. Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett 1997; 411(1): 32-8.
75. Papke RL. The kinetic properties of neuronal nicotinic receptors: genetic basis of functional diversity. Prog Neurobiol 1993; 41(4): 509-31.
76. Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 2004; 35(1): 1-8.
77. Conroy WG, Berg DK. Nicotinic receptor subtypes in the developing chick brain: appearance of a species containing the alpha4, beta2, and alpha5 gene products. Mol Pharmacol 1998; 53(3): 392-401.
78. Balestra B, Vailati S, Moretti M, Hanke W, Clementi F, Gotti C. Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype. Mol Pharmacol 2000; 58(2): 300-11.
79. Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels. Nature 1996; 380(6572): 347-51.
80. Whiteaker P, Peterson CG, Xu W, McIntosh JM, Paylor R, Beaudet AL, et al. Involvement of the alpha3 subunit in central nicotinic binding populations. J Neurosci 2002; 22(7): 2522-9.
81. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002; 53(4): 633-40.
82. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novere N, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374(6517): 65-7.
83. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 1999; 18(5): 1235-44.
84. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 1994; 653(1-2): 278-84.
85. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391(6663): 173-7.
86. Salminen O, Murphy KL, McIntosh JM, Drago, J, Marks MJ, Collins AC, et al. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 2004; 65(6): 1526-35.
87. Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, et al. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci 2003; 23(35): 11045-53.
88. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999; 398(6730): 805-10.
89. Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M, et al. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res 2000; 871(1): 66-74.
90. Zoli M. Neuronal Nicotinic Acetylcholine Receptors in Delopment and Aging. In: Clementi F, Fornasari D, Gotti C, editors. Handbook of Experimental Pharmacology. Berlin: Springer; 2000. p. 213-246.
91. Zhou ZJ. The function of the cholinergic system in the developing mammalian retina. Prog Brain Res 2001; 131: 599-613.
92. Feller MB. The role of nAChR-mediated spontaneous retinal activity in visual system development. J Neurobiol 2002; 53(4): 556-67.
93. Lipton SA, Kater SB. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival. Trends Neurosci 1989; 12(7): 265-70.
94. Pugh PC, Berg DK. Neuronal acetylcholine receptors that bind alpha-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J Neurosci 1994; 14(2): 889-96.
95. Zheng JQ, Felder M, Connor JA, Poo MM. Turning of nerve growth cones induced by neurotransmitters. Nature 1994; 368(6467): 140-4.
96. Quik M. Growth related role for the nicotinic α-Bungarotoxin receptors. In: Clarke PB, Quik M, Adlkofer F, Thurau K, editors. Advances in Pharmacological Sciences. Effects of Nicotine on Biological Systems 11. Basel: Birkhauser Verlag; 1995. p. 145-150.
97. Renshaw G, Rigby P, Self G, Lamb A, Goldie R. Exogenously administered alpha-bungarotoxin binds to embryonic chick spinal cord: implications for the toxin-induced arrest of naturally occurring motoneuron death. Neuroscience 1993; 53(4): 1163-72.
98. Laudenbach V, Medja F, Zoli M, Rossi FM, Evrard P, Changeux JP, et al. Selective activation of central subtypes of the nicotinic acetylcholine receptor has opposite effects on neonatal excitotoxic brain injuries. Faseb J 2002; 16(3): 423-5.
99. Berger F, Gage FH, Vijayaraghavan S. Nicotinic receptor-induced apoptotic cell death of hippocampal progenitor cells. J Neurosci 1998; 18(17): 6871-81.
100. Bansal A, Singer JH, Hwang BJ, Xu W, Beaudet A, Feller MB. Mice lacking specific nicotinic acetylcholine receptor subunits exhibit dramatically altered spontaneous activity patterns and reveal a limited role for retinal waves in forming ON and OFF circuits in the inner retina. J Neurosci 2000; 20(20): 7672-81.
101. Rossi FM, Pizzorusso T, Porciatti V, Marubio LM, Maffei L, Changeux JP. Requirement of the nicotinic acetylcholine receptor beta 2 subunit for the anatomical and functional development of the visual system. Proc Natl Acad Sci USA 2001; 98(11): 6453-8.
102. Newhouse P, Singh A, Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr Top Med Chem 2004; 4(3): 267-82.
103. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997; 52(6): 511-35.
104. Perry E, Martin-Ruiz C, Lee M, Griffiths M, Johnson M, Piggott M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000; 393(1-3): 215-22.
105. Ferrari R, Le Novere N, Picciotto MR, Changeux JP, Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 2002; 15(11): 1810-8.
106. Belluardo N, Mudo G, Blum M, Fuxe K. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 2000; 113(1-2): 21-34.
107. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000; 113(1-2): 117-20.
108. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001; 132(8): 1650-6.
109. Labarca C, Schwarz J, Deshpande P, Schwarz S, Nowak MW, Fonck C, et al. Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci USA 2001; 98(5): 2786-91.
110. Fonck C, Nashmi R, Deshpande P, Damaj MI, Marks MJ, Riedel A, et al. Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors. J Neurosci 2003; 23(7): 2582-90.
111. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 1997; 40(26): 4169-94.
112. McIntosh JM. Toxin Antagonists of the Neuronal Nicotinic Acetylcholine Receptors. In: Clementi F, Fornasari D, Gotti C, editors. Handbook of Experimental Pharmacology. Berlin: Springer; 2000. p. 455-476.
113. Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety 2002; 16(3): 89-92.
114. O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 2002; 1(4): 399-411.
115. Astles PC, Baker SR, Boot JR, Broad LM, Dell CP, Keenan M. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord 2002; 1(4): 337-48.
116. Nicke A, Wonnacott S, Lewis RJ. alpha-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes. Eur J Biochem 2004; 271(12): 2305-19.
117. Papke RL, Heinemann SF. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol Pharmacol 1994; 45(1): 142-9.
118. Luetje CW, Piattoni M, Patrick J. Mapping of ligand binding sites of neuronal nicotinic acetylcholine receptors using chimeric alpha subunits. Mol Pharmacol 1993; 44(3): 657-66.
119. Anand R, Nelson ME, Gerzanich V, Wells GB, Lindstrom J. Determinants of channel gating located in the N-terminal extracellular domain of nicotinic alpha7 receptor. J Pharmacol Exp Ther 1998; 287(2): 469-79.
120. Corringer PJ, Bertrand S, Bohler S, Edelstein SJ, Changeux JP, Bertrand D. Critical elements determining diversity in agonist binding and desensitization of neuronal nicotinic acetylcholine receptors. J Neurosci 1998; 18(2): 648-57.
121. Le Novere N, Grutter T, Changeux JP. Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites. Proc Natl Acad Sci USA 2002; 99(5): 3210-5.
122. Parker MJ, Beck A, Luetje CW. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity. Mol Pharmacol 1998; 54(6): 1132-9.
123. Gotti C, Moretti M, Maggi R, Longhi R, Hanke W, Klinke N, et al. Alpha7 and alpha8 nicotinic receptor subtypes immunopurified from chick retina have different immunological, pharmacological and functional properties. Eur J Neurosci 1997; 9(6): 1201-11.
124. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997; 280(1): 346-56.
125. Breining SR. Recent developments in the synthesis of nicotinic acetylcholine receptor ligands. Curr Top Med Chem 2004; 4(6): 609-29.
126. Kristufek D, Stocker E, Boehm S, Huck S. Somatic and prejunctional nicotinic receptors in cultured rat sympathetic neurones show different agonist profiles. J Physiol 1999; 516 ( Pt 3): 739-56.
127. Seale TW, Nael R, Singh S, Basmadjian G. Inherited, selective hypoanalgesic response to cytisine in the tail-flick test in CF-1 mice. Neuroreport 1998; 9(2): 201-5.
128. Museo E, Wise RA. Cytisine-induced behavioral activation: delineation of neuroanatomical locus of action. Brain Res 1995; 670(2): 257-63.
129. Canu Boido C, Sparatore F. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives. Farmaco 1999; 54(7): 438-51.
130. Carbonnelle E, Sparatore F, Canu-Boido C, Salvagno C, Baldani-Guerra B, Terstappen G, et al. Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur J Pharmacol 2003; 471(2): 85-96.
131. Imming P, Klaperski P, Stubbs MT, Seitz G, Gundisch D. Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands. Eur J Med Chem 2001; 36(4): 375-88.
132. Houlihan LM, Slater Y, Guerra DL, Peng JH, Kuo YP, Lukas RJ, et al. Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors. J Neurochem 2001; 78(5): 1029-43.
133. Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002: 53(4): 479-500.
134. Mike A, Castro NG, Albuquerque EX. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons. Brain Res 2000; 882(1-2): 155-68.
135. Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, et al. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 1995; 48(4): 774-82.
136. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 1994; 45(4): 563-9.
137. Dukat M, Glennon RA. Epibatidine: impact on nicotinic receptor research. Cell Mol Neurobiol 2003, 23(3): 365-78.
138. Gatley SJ, Ding YS, Brady D, Gifford AN, Dewey SL, Carroll FI, et al. In vitro and ex vivo autoradiographic studies of nicotinic acetylcholine receptors using [18F]fluoronochloroepibatidine in rodent and human brain. Nucl Med Biol 1998; 25(5): 449-54.
139. Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL. The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors. Mol Pharmacol 2004; 66(1): 14-24.
140. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000; 113(1-2): 169-81.
141. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156(12): 1931-7.
142. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997; 283(1): 235-46.
143. Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, et al. ABT-089: Pharmacological Properties of a Neuronal Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of Cognitive Disorders. CNS Drug Rev 2004; 10(2): 167-82.
144. Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, et al. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J Neurosci 2000; 20(8): 2783-91.
145. Bencherif M, Bane AJ, Miller CH, Dull GM, Gatto GJ. TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. Eur J Pharmacol 2000; 409(1): 45-55.
146. Chen Y, Sharples TJ, Phillips KG, Benedetti G, Broad LM, Zwart R, et al. The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology 2003; 45(3): 334-44.
147. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, et al. TC-1734: An Orally Active Neuronal Nicotinic Acetylcholine Receptor Modulator with Antidepressant, Neuro-protective and Long-Lasting Cognitive Effects. CNS Drug Rev 2004; 10(2): 147-66.
148. Kulak JM, Musachio JL, McIntosh JM, Quik M. Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther 2002; 303(2): 633-9.
149. Jain KK. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs 2004; 5(1): 76-81.
150. Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther 1998; 285(2): 787-94.
151. Boyce S, Webb JK, Shepheard SL, Russell MG, Hill RG, Rupniak NM. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 2000; 85(3): 443-50.
152. McIntosh JM, Azam L, Staheli S, Dowell C, Lindstrom JM, Kuryatov A, et al. Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. Mol Pharmacol 2004; 65(4): 944-52.
153. Barabino B, Vailati S, Moretti M, McIntosh JM, Longhi R, Clementi F, et al. An alpha4beta4 nicotinic receptor subtype is present in chick retina: identification, characterization and pharmacological comparison with the transfected alpha4beta4 and alpha6beta4 subtypes. Mol Pharmacol 2001; 59(6): 1410-7.
154. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001; 21(5): 1452-63.
155. Gotti C, Balestra B, Moretti M, Rovati GE, Maggi L, Rossoni G, et al. 4-Oxystilbene compounds are selective ligands for neuronal nicotinic alphaBungarotoxin receptors. Br J Pharmacol 1998; 124(6): 1197-206.
156. Maggi L, Palma E, Eusebi F, Moretti M, Balestra B, Clementi F, et al. Selective effects of a 4-oxystilbene derivative on wild and mutant neuronal chick alpha7 nicotinic receptor. Br J Pharmacol 1999; 126(1): 285-95.
157. Di Angelantonio S, Nistri A, Moretti M, Clementi F, Gotti C. Antagonism of nicotinic receptors of rat chromaffin cells by N,N, N-trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium iodide: a patch clamp and ligand binding study. Br J Pharmacol 2000; 129(8): 1771-9.
158. Dwoskin LP, Wilkins LH, Pauly JR, Crooks PA. Development of a novel class of subtype-selective nicotinic receptor antagonist: pyridine-N-substituted nicotine analogs. Ann N Y Acad Sci 1999; 868: 617-9.
159. el-Bizri H, Clarke PB. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine administered in vivo. Br J Pharmacol 1994; 111(2): 414-8.
160. Martin BR, Onaivi ES, Martin TJ. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 1989; 38(20): 3391-7.
161. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89(2): 337-43.
162. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7(6): 525-35.
163. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295(1): 321-7.
164. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 1999; 72(3): 1117-24.
165. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288(1): 88-92.
166. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-8.
167. Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002; 63(2): 89-98.
168. Miller DK, Crooks PA, Dwoskin LP. Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology 2000; 39(13): 2654-62.
169. Gallardo KA, Leslie FM. Nicotine-stimulated release of [3H]norepinephrine from fetal rat locus coeruleus cells in culture. J Neurochem 1998; 70(2): 663-70.
170. Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP. Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav 2003; 74(2): 279-86.
171. Clarke PB, Chaudieu I, el-Bizri H, Boksa P, Quik M, Esplin BA, et al. The pharmacology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion. Br J Pharmacol 1994; 111(2): 397-405.
172. Clarke PB. Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine. Br J Pharmacol 1984; 83(2): 527-35.
173. Marenco T, Bernstein S, Cumming P, Clarke PB. Effects of nicotine and chlorisondamine on cerebral glucose utilization in immobilized and freely-moving rats. Br J Pharmacol 2000; 129(1): 147-55.
174. Reuben M, Louis M, Clarke PB. Persistent nicotinic blockade by chlorisondamine of noradrenergic neurons in rat brain and cultured PC12 cells. Br J Pharmacol 1998; 125(6): 1218-27.
175. Luo S, Kulak JM, Cartier GE, Jacobsen RB, Yoshikami D, Olivera BM, et al. alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. J Neurosci 1998; 18(21): 8571-9.
176. Dutton JL, Bansal PS, Hogg RC, Adams DJ, Alewood PF, Craik DJ. A new level of conotoxin diversity, a non-native disulfide bond connectivity in alpha-conotoxin AuIB reduces structural definition but increases biological activity. J Biol Chem 2002; 277(50): 48849-57.
177. Johnson DS, Martinez J, Elgoyhen AB, Heinemann SF, McIntosh JM. alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors. Mol Pharmacol 1995; 48(2): 194-9.
178. Ellison M, McIntosh JM, Olivera BM. Alpha-conotoxins ImI and ImII. Similar alpha 7 nicotinic receptor antagonists act at different sites. J Biol Chem 2003; 278(2): 757-64.
179. Codignola A, McIntosh JM, Cattaneo MG, Vicentini LM, Clementi F, Sher E. alpha-Conotoxin imperialis I inhibits nicotine-evoked hormone release and cell proliferation in human neuroendocrine carcinoma cells. Neurosci Lett 1996; 206(1): 53-6.
180. Codignola A, Tarroni P, Cattaneo MG, Vicentini LM, Clementi F, Sher E. Serotonin release and cell proliferation are under the control of alpha-bungarotoxin-sensitive nicotinic receptors in small-cell lung carcinoma cell lines. FEBS Lett 1994; 342(3): 286-90.
181. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. J Biol Chem 1996; 271(13): 7522-8.
182. Vailati S, Hanke W, Bejan A, Barabino B, Longhi R, Balestra B, et al. Functional alpha6-containing nicotinic receptors are present in chick retina. Mol Pharmacol 1999; 56(1): 11-9.
183. Dowell C, Olivera BM, Garrett JE, Staheli ST, Watkins M, Kuryatov A, et al. Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors. J Neurosci 2003; 23(24): 8445-52.
184. Luo S, Nguyen TA, Cartier GE, Olivera BM, Yoshikami D, McIntosh JM. Single-residue alteration in alpha-conotoxin PnIA switches its nAChR subtype selectivity. Biochemistry 1999; 38(44): 14542-8.
185. Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002; 8(4): 405-26.
186. Woodruff-Pak DS, Vogel RW, 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 2001; 98(4): 2089-94.
187. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61(5): 1222-34.
188. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, et al. Cloning of an avermectin-sensitive glutamategated chloride channel from Caenorhabditis elegans. Nature 1994; 371(6499): 707-11.
189. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP, et al. Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998; 53(2): 283-94.
190. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, et al. 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002: 43(3): 374-84.
191. Lena C, Changeux JP. Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci 1993; 16(5): 181-6.
192. Albuquerque EX, Pereira EF, Alkondon M, Schrattenholz A, Maelicke A. Nicotinic acetylcholine receptors on hippocampal neurons: distribution on the neuronal surface and modulation of receptor activity. J Recept Signal Transduct Res 1997; 17(1-3): 243-66.
193. Akasu T, Koketsu K. 5-Hydroxytryptamine decreases the sensitivity of nicotinic acetylcholine receptor in bull-frog sympathetic ganglion cells. J Physiol 1986; 380: 93-109.
194. Vijayaraghavan S, Schmid HA, Mapp KS. Serotonin modulates nicotinic responses of adrenal chromaffin cells. J Neurochem 1993; 61(1): 324-31.
195. Garcia-Colunga J, Miledi R. Effects of serotonergic agents on neuronal nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 1995; 92(7): 2919-23.
196. Cross KM, Foreman RC, Chad JE. Enhancement by 5-hydroxytryptamine and analogues of desensitization of neuronal and muscle nicotinic receptors expressed in Xenopus oocytes. Br J Pharmacol 1995; 114(8): 1636-40.
197. Fucile S, Palma E, Eusebi F, Miledi R. Serotonin antagonizes the human neuronal alpha7 nicotinic acetylcholine receptor and becomes an agonist after L248T alpha7 mutation. Neuroscience 2002; 110(1): 169-79.
198. Nagata K, Aistrup GL, Huang CS, Marszalec W, Song JH, Yeh JZ, et al. Potent modulation of neuronal nicotinic acetylcholine receptor-channel by ethanol. Neurosci Lett 1996; 217(2-3): 189-93.
199. Larsson A EJA. Neurochemical and behavioural studies on ethanol and nicotine interactions. Neurosci Biobehav Rev 2004; 27: 713-720.
200. Dohrman DP, Reiter CK. Ethanol modulates nicotine-induced upregulation of nAChRs. Brain Res 2003; 975(1-2): 90-8.
201. Covernton PJ, Connolly JG. Differential modulation of rat neuronal nicotinic receptor subtypes by acute application of ethanol. Br J Pharmacol 1997; 122(8): 1661-8.
202. Sala F, Mulet J, Valor LM, Criado M, Sala S. Effects of benzothiazepines on human neuronal nicotinic receptors expressed in Xenopus oocytes. Br J Pharmacol 2002; 136(2): 183-92.
203. Gandia L, Villarroya M, Sala F, Reig JA, Viniegra S, Quintanar JL, et al. Inhibition of nicotinic receptor-mediated responses in bovine chromaffin cells by diltiazem. Br J Pharmacol 1996; 118(5): 1301-7.
204. Donnelly-Roberts DL, Arneric SP, Sullivan JP. Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists. Biochem Biophys Res Commun 1995; 213(2): 657-62.
205. Herrero CJ, Garcia-Palomero E, Pintado AJ, Garcia AG, Montiel C. Differential blockade of rat alpha3beta4 and alpha7 neuronal nicotinic receptors by omega-conotoxin MVIIC, omega-conotoxin GVIA and diltiazem. Br J Pharmacol 1999; 127(6): 1375-87.
206. Wonnacott S, Thorne B. Separation of pre- and post-synaptic receptors on Percoll gradients. Biochem Soc Trans 1990; 18(5): 885-6.
207. Perry DC, Davila-Garcia MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999; 289(3): 1545-52.
208. Buisson B, Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 2002; 23(3): 130-6.
209. Miao H, Liu C, Bishop K, Gong ZH, Nordberg A, Zhang X. Nicotine exposure during a critical period of development leads to persistent changes in nicotinic acetylcholine receptors of adult rat brain. J Neurochem 1998; 70(2): 752-62.
210. Parker SL, Fu Y, McAllen K, Luo J, McIntosh JM, Lindstrom JM, el al. Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the alpha6 subunit. Mol Pharmacol 2004; 65(3): 611-22.
211. Marks MJ, JR P, SD G, ES D, I H-B, Heinemann S, et al. nicotine binding and nicotinic receptor mRNA after chronic nicotine treatment. J of neurosci 1992; 12: 2765-2784.
212. Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 1997; 17(15): 5747-59.
213. Harkness PC, Millar NS. Changes in conformation and subcellular distribution of alpha4beta2 nicotinic acetylcholine receptors revealed by chronic nicotine treatment and expression of subunit chimeras. J Neurosci 2002; 22(23): 10172-81.
214. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol 2003; 63(2): 332-41.
215. Gopalakrishnan M, Molinari EJ, Sullivan JP. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol Pharmacol 1997; 52(3): 524-34.
216. Pauly JR, Marks MJ, Robinson SF, van de Kamp JL, Collins AC. Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels. J Pharmacol Exp Ther 1996; 278(1): 361-9.
217. Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J. Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 1997; 283(2): 675-83.
218. Wang F, Nelson ME, Kuryatov A, Olale F, Cooper J, Keyser K, et al. Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells. J Biol Chem 1998; 273(44): 28721-32.
219. Sallette J, Bohler S, Benoit P, Soudant M, Pons S, Le Novere N, et al. An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotine. J Biol Chem 2004; 279(18): 18767-75.
220. Kawai H, Berg DK. Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure. J Neurochem 2001; 78(6): 1367-78.
221. Ciementi F, Court J, Perry E. Involvement of Neuronal Nicotinic Receptors In Disease. In: Clementi F, Fornasari D, Gotti C, editors. Handbook of Experimental Pharmacology. Berlin: Springer; 2000. p. 751-778.
222. Grando SA, Kawashima K, Wessler I. Introduction: the non-neuronal cholinergic system in humans. Life Sci 2003; 72(18-19): 2009-12.
223. Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 2002; 53(4): 641-55.
224. Araki H, Kobayashi Y, Hashimoto Y, Futagami K, Kawasaki H, Gomita Y. Characteristics of flurothyl-induced seizures and the effect of antiepileptic drugs on flurothyl-induced seizures in Mongolian gerbils. Pharmacol Biochem Behav 2002; 74(1): 141-7.
225. Rezvani AH, Levin ED. Cognitive effects of nicotine. Biol Psychiatry 2001; 49(3): 258-67.
226. Kukull WA. The association between smoking and Alzheimer's disease: effects of study design and bias. Biol Psychiatry 2001; 49(3): 194-9.
227. Burghaus L, Schutz U, Krempel U, Lindstrom J, Schroder H. Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat Disord 2003; 9(5): 243-6.
228. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002; 23(4-5): 581-94.
229. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000; 43(1-3): 274-82.
230. Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992; 108(4): 485-94.
231. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996; 47(1): 166-77.
232. Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol Pharmacol 2001; 59(4): 674-83.
233. Scheffer IE, Berkovic SF. The genetics of human epilepsy. Trends Pharmacol Sci 2003; 24(8): 428-33.
234. Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. Nat Genet 1995; 10(1): 117-8.
235. Raggenbass M, Bertrand D. Nicotinic receptors in circuit excitability and epilepsy. J Neurobiol 2002; 53(4): 580-9.
236. Sutor B, Zolles G. Neuronal nicotinic acetylcholine receptors and autosomal dominant nocturnal frontal lobe epilepsy: a critical review. Pflugers Arch 2001; 442(5): 642-51.
237. Gahring LC, Persiyanov K, Dunn D, Weiss R, Meyer EL, Rogers SW. Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus. J Comp Neurol 2004; 468(3): 334-46.
238. Sanberg PR, Fogelson HM, Manderscheid PZ, Parker KW, Norman AB, McConville BJ. Nicotine gum and haloperidol in Tourette's syndrome. Lancet 1988; 1(8585): 592.
239. McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, et al. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 1991; 148(6): 793-4.
240. McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry 1992; 31(8): 832-40.
241. Dursun SM, Reveley MA, Bird F, Stirton F. Longlasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 1994; 344(8936): 1577.
242. Silver AA, Shytle RD, Phillipp MK, Sanberg PR. Transdermal nicotine in Tourette's syndrome. In: Clarke PB, Quik M, Adlkofer F, Thurau K, editors. Advances in Pharmacological Sciences. Effects of Nicotine on Biological Systems II. Basel: Birkhauser Verlag; 1995. p. 293-299.
243. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002; 125(Pt 7): 1483-95.
244. Martin-Ruiz CM, Lee M, Perry RH, Baumann M, Court JA, Perry EK. Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res 2004; 123(1-2): 81-90.
245. Bobee S, Mariette E, Tremblay-Leveau H, Caston J. Effects of early midline cerebellar lesion on cognitive and emotional functions in the rat. Behav Brain Res 2000; 112(1-2): 107-17.
246. Botez MI, Botez T, Elie R, Attig E. Role of the cerebellum in complex human behavior. Ital J Neurol Sci 1989; 10(3): 291-300.
247. Quay HC. Inhibition and attention deficit hyperactivity disorder. J Abnorm Child Psychol 1997; 25(1): 7-13.
248. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001; 70(4): 561-70.
249. Provost SC, Woodward R. Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology (Berl) 1991; 104(4): 536-40.
250. Perry EK, Lee ML, Martin-Ruiz CM, Court JA, Volsen SG, Merrit J, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001; 158(7): 1058-66.
251. Poirier MF, Canceil O, Bayle F, Millet B, Bourdel MC, Moatti C, et al. Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(3): 529-37.
252. Patkar AA, Sterling RC, Leone FT, Lundy A, Weinstein SP. Relationship between tobacco smoking and medical symptoms among cocaine-, alcohol-, and opiate-dependent patients. Am J Addict 2002; 11(3): 209-18.
253. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38(1): 22-33.
254. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull 1996; 22(3): 431-45.
255. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 2003; 54(11): 1222-33.
256. Leonard S, Gault J, Hopkins J, Logel J, Vianzon F, Short M, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002; 59(12): 1085-96.
257. Gault J, Hopkins J, Berger R, Drebing C, Logel J, Walton C, et al. Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects. Am J Med Genet 2003; 123B(1): 39-49.
258. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002; 13(9): 1097-106.
259. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Design 2005; 11(15): 1975-2003.
260. Saini R, Tutrone WD, Weinberg JM. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr Pharm Design 2005; 11(2): 273-80.
261. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Design 2004, 10(25): 3177-84.